Common Stock, par value $0.01 per share
- Symbol
- ZTS
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 7.01, 9.01 · 8-K
ZOETIS INC.
ZTSNYSEEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 8, 2026, the Board of Directors (the "Board") of Zoetis Inc.…
Press release in this filing
Zoetis Appoints Iris Knobloch to its Board of Directors →Company context
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
Current securities
Registered securities in this filing
Zoetis Inc. · 8-K · Filed 2026-10-13
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 8, 2026, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Iris Knobloch to the Board, effective as of December 1, 2026, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appointment of Ms. Knobloch, the size of the Board will be increased from twelve to thirteen members effective as of December 1, 2026. Ms. Knobloch has been appointed to serve on the Board’s Corporate Governance Committee.
Ms. Knobloch was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Knobloch that would be reportable under Item 404(a) of Regulation S-K. The Company’s non-employee director compensation program is described under the caption “Compensation of Directors” in the Company’s proxy statement for its 2026 Annual Meeting of Shareholders filed with the Securities and Exchange Commission on April 8, 2026. Ms. Knobloch will be eligible for participation in such non-employee director compensation program.
In connection with her appointment as a member of the Board, the Company will enter into its standard form of indemnification agreement with Ms. Knobloch. The form of indemnification agreement was previously filed by the Company as Exhibit 10.19 to Amendment No. 4 to the Company’s Registration Statement on Form S-1 (File No. 333-183254), as originally filed with the Securities and Exchange Commission on August 13, 2012, and subsequently amended.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On October 13, 2026, the Company issued a press release announcing the appointment of Ms. Knobloch. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.